Anshul Maheshwari Sells 2,418 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 2,418 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.87, for a total transaction of $33,537.66. Following the sale, the chief financial officer now directly owns 198,762 shares in the company, valued at approximately $2,756,828.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

SI-BONE Stock Down 1.0 %

NASDAQ:SIBN traded down $0.14 during trading hours on Tuesday, hitting $14.18. The company’s stock had a trading volume of 234,859 shares, compared to its average volume of 400,173. SI-BONE, Inc. has a 52-week low of $11.76 and a 52-week high of $23.25. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $591.16 million, a P/E ratio of -13.01 and a beta of 1.20. The stock has a fifty day moving average of $14.13 and a 200-day moving average of $15.50.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The business had revenue of $39.97 million for the quarter, compared to the consensus estimate of $38.95 million. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. During the same quarter in the prior year, the business posted ($0.30) EPS. On average, equities analysts forecast that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

Analyst Ratings Changes

SIBN has been the topic of several recent research reports. Truist Financial cut their target price on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Needham & Company LLC lowered their target price on SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Morgan Stanley reduced their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE has an average rating of “Buy” and an average price target of $23.00.

Institutional Trading of SI-BONE

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. Champlain Investment Partners LLC grew its position in shares of SI-BONE by 104.8% in the 1st quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock valued at $40,158,000 after buying an additional 1,255,610 shares during the last quarter. Bellevue Group AG grew its holdings in shares of SI-BONE by 810.5% during the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock worth $18,661,000 after purchasing an additional 1,014,756 shares during the last quarter. American Century Companies Inc. increased its position in shares of SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of SI-BONE during the fourth quarter worth about $6,721,000. Finally, Paradigm Capital Management Inc. NY lifted its holdings in shares of SI-BONE by 24.7% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after purchasing an additional 267,100 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.